Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Acta Pharmaceutica Sinica. B|September 30, 2022
LncRNA <i>DACH1</i> protects against pulmonary fibrosis by binding to SRSF1 to suppress <i>CTNNB1</i> accumulationJian Sun, Tongzhu Jin, Zhihui Niu, et al.
Gigabyte (Hong Kong, China)|May 7, 2025
Efficiently constructing complete genomes with CycloneSEQ to fill gaps in bacterial draft assembliesHewei Liang, Yuanqiang Zou, Mengmeng Wang, et al.
Experimental & Molecular Medicine|June 30, 2024
YAP1 inhibits the senescence of alveolar epithelial cells by targeting Prdx3 to alleviate pulmonary fibrosisWei Su, Yingying Guo, Qianqian Wang, et al.
Acta Pharmaceutica Sinica. B|July 14, 2025
SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblastsTongzhu Jin, Huiying Gao, Yuquan Wang, et al.
Nature Communications|August 3, 2023
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II studyDongliang Bian, Liangdong Sun, Junjie Hu, et al.
Nature Communications|February 24, 2025
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trialChengxiang Yi, Dongliang Bian, Jue Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2019
Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung CancerJie Dai, Ming Liu, Yang Yang, et al.
Eclinicalmedicine|January 1, 2026
Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trialTao Ge, Hongyi Zhang, Xinsheng Zhu, et al.
BMC Medicine|December 29, 2022
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trialXinsheng Zhu, Liangdong Sun, Nan Song, et al.
Nature Communications|April 1, 2025
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trialDongliang Bian, Shuyu Ji, Yue Liu, et al.
Pageof 10